Join the 'Namzaric' group to help and get support from people like you.
Posted 29 Sep 2017 by Drugs.com
FRIDAY, Sept. 29, 2017 – A new test that checks for multiple gene variants linked with Alzheimer's disease may be more effective than testing for a single genetic variant, a new study suggests. The genetic variant APOE E4 is regarded as the strongest genetic predictor of whether a person is likely to develop the memory-robbing disease. But it's present in only 10 to 15 percent of people. And recent research suggests its impact has been overestimated, the study authors said. They developed a test that estimates the risk of Alzheimer's in the 85 to 90 percent of people who don't have at least one copy of APOE E4 but still have other gene variants that put them at risk of Alzheimer's. The test is called the polygenic hazard score (PHS). The researchers reviewed five years of data from nearly 1,100 Americans without dementia. They concluded that the new test could predict how long it would ... Read more
Posted 8 Mar 2017 by Drugs.com
TUESDAY, March 7, 2017 – A drug used to treat Alzheimer's disease should not be prescribed to people with milder mental impairment without first giving them a genetic test, a new study urges. The drug is donepezil (brand name: Aricept). Donepezil could speed mental decline in someone with mild cognitive impairment who has a specific genetic variation, according to Sophie Sokolow, an associate professor at the UCLA School of Nursing. She and her colleagues found that patients with the K-variant of the butyrylcholinesterase (BChE) gene who took donepezil deteriorated faster than those who took a placebo. Donepezil is approved in the United States to treat Alzheimer's disease but not mild cognitive impairment – the stage between normal age-related decline and dementia. However, doctors often prescribe it "off-label" for patients with mild cognitive impairment, the study authors said. For ... Read more
Posted 3 Aug 2015 by Drugs.com
MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more
Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Galantamine, Rivastigmine, Arteriosclerotic Dementia, Cachexia, Namzaric, Lewy Body Dementia, Razadyne ER, Tacrine, Arteriosclerotic Dementia w/ Depressive Features, Cognex, Razadyne, Reminyl, Aricept ODT